Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Target Price at $43.38

Maze Therapeutics, Inc. (NASDAQ:MAZE) has been given an average rating of “Buy” by the twelve analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $43.3750.

Several brokerages recently issued reports on MAZE. HC Wainwright boosted their price target on shares of Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Guggenheim reaffirmed a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Friday, December 19th. JPMorgan Chase & Co. upped their target price on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, September 29th. BTIG Research increased their target price on Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Finally, Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th.

Maze Therapeutics Stock Performance

MAZE stock opened at $39.77 on Tuesday. The company has a market capitalization of $1.91 billion and a PE ratio of -1.90. Maze Therapeutics has a one year low of $6.71 and a one year high of $43.29. The company’s 50 day moving average price is $37.00 and its two-hundred day moving average price is $24.97.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 45,000 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Atul Dandekar sold 72,400 shares of the stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the transaction, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. This trade represents a 87.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 132,500 shares of company stock valued at $5,371,980 in the last 90 days.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. purchased a new position in shares of Maze Therapeutics in the first quarter worth $796,000. Deutsche Bank AG purchased a new stake in Maze Therapeutics in the 1st quarter worth $98,000. Invesco Ltd. bought a new position in shares of Maze Therapeutics during the 1st quarter valued at about $226,000. Nuveen LLC purchased a new position in shares of Maze Therapeutics during the first quarter valued at about $125,000. Finally, Corebridge Financial Inc. bought a new stake in shares of Maze Therapeutics in the first quarter worth about $48,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.